Moléculas inflamatorias y marcadores de lesión endotelial en la isquemia cerebral : participación en el deterioro neurológico y la transformación hemorrágiaca

Consultable des del TDXTítol obtingur de la portada digitalitzadaLos mecanismos implicados en el deterioro neurológico precoz (DNP) y en la transformación hemorrágica (TH) de la lesión isquémica cerebral no se conocen con exactitud. Estudios previos habían demostrado la asociación de niveles elevados de TNF-a e IL-6 con el DNP en pacientes con isquemia cerebral independientemente del mecanismo ictal. Sin embargo, los mecanismos relacionados con el DNP en pacientes con infarto lacunar no se conocían con exactitud. Con el objetivo de determinar si los mecanismos inflamatorios participaban en la progresión y el pronóstico funcional de estos pacientes se determinaron los niveles de TNF-a, IL-6 e ICAM-1 en el momento del ingreso en 113 pacientes con ictus lacunar de 14 pg/mL y de ICAM-1 > 208 pg/mL se asociaban de manera independiente tanto con el DNP como con el mal pronóstico funcional evaluado a los 3 meses. En cuanto a la TH, se había demostrado la asociación de niveles elevados de MMP-9 y la aparición de TH exclusivamente en pacientes con ictus de mecanismo cardioembólico por lo que se analizaron los niveles de esta molécula en 250 pacientes con ictus hemisférico de 14 pg/mL and ICAM-1 > 208 pg/mL were independently associated with both END and poor outcome at 3 months. On the other hand, the association between high levels of matrix metaloproteinase-9 (MMP-9) and secondary bleeding in patients with cardiembolic ischemic stroke had been already published. However, there were no data about the HT predictive capacity of MMP-9 in patients with other stroke subtypes. The association between high levels of MMP-9 and the development of HT was determined in 250 patients with hemispheric ischemic stroke within the first 24 hours of symptoms' onset. The results demonstrated that those patients with HT had significantly higher levels of MMP-9 at admission compared to those without secondary bleeding. Logistic regression analysis showed that MMP-9 levels ≥ 140 ng/mL were independently associated with HT after adjustment for potential confounders. Moreover, MMP-9 levels ≥ 140 ng/mL predicted the development of HT with a sensitivity, especificity, negative predictive value (NPV) and positive predictive value (PPV) of 87%, 90%, 61% and 97%, respectively. Finally, the association between the levels of cellular-Fibronectin (c-Fn), taken as a more specific marker of endothelial damage, and the development of HT in 87 patients who received thrombolytic treatment with rt-PA was evaluated. In order to compare the predictive capacity of MMP-9 and c-Fn levels, the levels of MMP-9 were also analyzed in this group of patients. The results demonstrated that patients with HT had significantly higher c-Fn as well as MMP-9 levels before the administration of the treatment. The levels of c-Fn were also higher in patients with symptomatic HT whereas no differences were found in MMP-9 levels between symptomatic and asymptomatic HT. Logistic regression analysis showed that c-Fn levels was the only variable associated with HT development after adjustment of potential confounders, which included MMP-9 levels. Levels of c-Fn ≥ 3.6 µg/mL predicted the development of hemorrhagic infarction type 2 and parenchymal hemorrhage (types of HT that has been reported to occur more often in patients treated with rt-PA) with a sensitivity of 100%, specificity of 96%, NPV of 44% and PPV of 100%, whereas the sensitivity, specificity, NPV and PPV of MMP-9 levels ≥ 140 ng/mL were 81%, 88%, 41% and 98%, respectively. These results were observed both in patients treated within 6 hours and within 3 hours from symptoms' onset. In conclusion, the results suggest that inflammation contributes to brain injury in patients with lacunar stroke and confirm that high plasma MMP-9 concentration is an independent predictor of HT in patients with acute ischemic stroke. Moreover, high plasma c-Fn levels are significantly associated with subsequent HT in stroke patients treated with rt-PA, so plasma c-Fn determinations might be useful in clinical practice to improve the risk/benefit ratio of thrombolytic treatment